- 10Sep, 2025
Podcast Interview: The Bio Report: Overcoming Antibiotic Resistance Listen to the podcast here. Antimicrobial resistance is projected to kill up to 10 million people a year by 2050. One particular area of concern is drug-resistant gonorrhea, where existing therapies are being exhausted. Taxis Pharmaceuticals is [...]
TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, discusses dihydrofolate reductase inhibitors as a novel approach to combat resistant Neisseria gonorrhoeae, a rapidly spreading, deadly, and highly resistant strain of Neisseria gonorrhoeae.
TAXIS Pharmaceuticals has named two industry professionals with extensive biopharma experience, Joeseph DePinto, MBA, and Frank Carlo Pasqualone, MBA, to its Board of Directors.
A conversation with Gregory G. Mario and Ajit K. Parhi, Ph.D., TAXIS Pharmaceuticals originally published in Drug Discovery Online.
- 15Jul, 2025
TAXIS has received a $2.9 million grant to further advance R&D efforts for its dihydrofolate reductase inhibitors (DHFRIs) as a novel approach to combat multi-drug resistant gonorrhea, a rapidly spreading deadly and highly resistant strain of Neisseria gonorrhoeae.
- 17Dec, 2024
Understanding the mechanisms behind antibiotic resistance reveals the pressing need for innovative solutions in the pharmaceutical landscape. Presenting TAXIS Pharmaceuticals' Commitment to Innovation: TXA709. TAXIS is dedicated to developing novel therapies that specifically target resistant strains of bacteria.
- 18Nov, 2024
Our new white paper delves into the global scope of AMR, shedding light on its widespread impact and the variability of its effects across different regions. The paper outlines actionable strategies to combat AMR, such as enhancing global surveillance systems, advocating for responsible antibiotic use, investing in the development of innovative treatments, and fostering international collaboration.
Frank Carlo Pasqualone, MBA
Joe DePinto, MBA
Gregory G. Mario, MBA, President and CEO